0001628280-19-014784.txt : 20191205 0001628280-19-014784.hdr.sgml : 20191205 20191205170838 ACCESSION NUMBER: 0001628280-19-014784 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191202 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20191205 DATE AS OF CHANGE: 20191205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 191270970 BUSINESS ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 8-K 1 guardant8-klanmanretirement.htm LANMAN RETIREMENT Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
 
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 2, 2019
 
GUARDANT HEALTH, INC.
(Exact name of registrant as specified in its charter)
 

 
 
 
 
 
Delaware
 
0001-576280
 
45-4139254
 
 
 
 
 
(State or other jurisdiction
of incorporation or organization)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)

505 Penobscot Dr.
Redwood City, California 94063
(Address of principal executive offices) (Zip Code)
855-698-8887
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ý

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00001
GH
  The Nasdaq Stock Market LLC





Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On December 2, 2019, Richard Lanman, M.D., the Chief Medical Officer of Guardant Health, Inc. (the “Company”), notified the Company of his decision to retire, effective as of December 31, 2019. Dr. Lanman has served as the Company’s Chief Medical Officer since 2014 and played a key role in establishing and executing the Company’s clinical development and physician education programs.  The Company is initiating a search to identify a new Chief Medical Officer, and Dr. Lanman intends to continue with the Company as an advisor to facilitate a successful transition. 




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
GUARDANT HEALTH, INC.
 
 
 
 
Date:
December 5, 2019
 
 
 
 
By:
/s/ Helmy Eltoukhy
 
 
 
Helmy Eltoukhy
 
 
 
Chief Executive Officer